5 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow Hyperinsulinemia: new trials by email Literature Review of Hyperinsulinemia trials Research Report on Hyperinsulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Effect of Insulin Lowering on Lipogenesis Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70% - Hyperinsulinemia, Insulin Resistance | Phase 1 | Recruiting | Columbia University | 25 | 2026-07-01 | 2026-07-06 |
| Diazoxide Suppression Test P&F Study Diazoxide, 3 mg/kg per dose - Insulin Resistance, Hyperinsulinemia | Phase 1 | Terminated | Columbia University | 1 | 2024-10-23 | 2026-08-07 |
| Graded Insulin Suppression Test P&F Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min - Insulin Resistance, Hyperinsulinemia | Phase 1 | Completed | Columbia University | 20 | 2024-09-16 | 2026-10-16 |
| Pancreatic Clamp in NAFLD Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Prediabetic State | Phase 1 | Completed | Columbia University | 18 | 2023-08-29 | 2026-01-12 |
| Glycemic Effect of Diazoxide in NAFLD Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo - Hyperinsulinemia, Insulin Resistance | Phase 1 | Completed | Columbia University | 22 | 2023-08-01 | 2026-09-30 |
| Effect of Alpelisib in Healthy Volunteers Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro - Insulin Resistance, Hyperinsulinemia | Phase 1 | Completed | Columbia University | 23 | 2023-05-09 | 2023-12-21 |
| Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation Insulin - Hyperinsulinemia | Phase 1 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 16 | 1997-03-01 | 2008-03-04 |
Hyperinsulinism (8) · Insulin Resistance (8) · Non-alcoholic Fatty Liver Disease (5) · Obesity (5) · Prediabetic State (4) · Diabetes Mellitus (3) · Diabetes Mellitus, Type 2 (2) · Dyslipidemias (1)
Glucose Metabolism Disorders (8) · Metabolic Diseases (8) · Nutritional and Metabolic Diseases (8) · Endocrine System Diseases (7) · Body Weight (5) · Digestive System Diseases (5) · Fatty Liver (5) · Liver Diseases (5) · Nutrition Disorders (5) · Overnutrition (5) · Overweight (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Diabetes Mellitus (4) · Lipid Metabolism Disorders (1)
Insulin (4) · Diazoxide (3) · Glucagon (3) · Glucose (3) · Octreotide (3) · Deuterium Oxide (2) · Human Growth Hormone (2) · Alpelisib (1) · Glucose Tolerance Test (1) · Water (1) · microcrystalline cellulose (1)
Columbia University (7) · National Heart, Lung, and Blood Institute (NHLBI) (1)
United States (8)
Joshua R Cook, MD, PhD (6) · Joshua R. Cook, MD, PhD (1)
K12DK133995 (2), P30DK063608 (2), K23DK140614 (1)